Falagas Matthew E, Rafailidis Petros I
Alfa Institute of Biomedical Sciences, Athens, Greece.
Crit Care. 2007;11(3):134. doi: 10.1186/cc5911.
There has been controversy regarding the mortality directly attributed to Acinetobacter baumannii infections. Data from six case-control studies have been recently added to the literature regarding the attributable mortality of A. baumannii infections during the past months. The information from these studies, added to the previous knowledge on this issue, provides evidence that A. baumannii infections are indeed associated with increased mortality. In addition, there is relevant evidence from studies examining the effect of inappropriate treatment on mortality; specifically, inappropriate treatment of A. baumannii infections has been associated with excess mortality. We believe that the accumulated data suggest that attributable mortality due to A. baumannii infections should no longer be a controversial issue. The efforts of the scientific community interested in this pathogen should therefore be directed to the development and introduction of new antibiotics effective against multidrug-resistant and pandrug-resistant A. baumannii as well as the implementation of infection control measures that may help us in the control of the increasing problem of A. baumannii infections.
关于鲍曼不动杆菌感染直接导致的死亡率一直存在争议。在过去几个月里，六项病例对照研究的数据最近被添加到关于鲍曼不动杆菌感染归因死亡率的文献中。这些研究的信息，加上此前关于这个问题的知识，提供了证据表明鲍曼不动杆菌感染确实与死亡率增加有关。此外，有关于不当治疗对死亡率影响的研究的相关证据；具体而言，鲍曼不动杆菌感染的不当治疗与额外死亡率有关。我们认为，积累的数据表明，鲍曼不动杆菌感染导致的归因死亡率不应再是一个有争议的问题。因此，对这种病原体感兴趣的科学界的努力应指向开发和引入对多重耐药和泛耐药鲍曼不动杆菌有效的新抗生素，以及实施可能有助于我们控制日益严重的鲍曼不动杆菌感染问题的感染控制措施。
